Purpose: To determine the levels of bone and cartilage turnover markers in men with ankylosing spondylitis (AS) and to investigate their associations with disease activity, bone mineral density, and radiographic damage of the spine.

Patients and Methods: This cross-sectional study enrolled 35 men with newly diagnosed AS. The bone mineral densities (BMD) of their lumbar spines and proximal femurs, Bath AS Disease Activity Index (BASDAI), and Bath AS Radiographic Index (BASRI) were evaluated. Urinary C-terminal telopeptide fragments of type I collagen (CTX-I) and type II collagen (CTX-II) levels were determined by enzyme-linked immunosorbent assay, and serum levels of bone-specific alkaline phosphatase (BALP) and osteocalcin were determined by an enzyme immunoassay. Levels of biochemical markers were compared with those of 70 age-matched healthy men.

Results: Patients with AS had significantly higher mean urinary CTX-I and CTX-II levels than control subjects \( (p < 0.05) \). Elevated urinary CTX-I levels correlated well with BASDAI, femoral BMD, and femoral T score \( (p < 0.05) \), and elevated urinary CTX-II levels correlated well with spinal BASRI \( (p < 0.05) \) in patients with AS. Mean serum BALP and osteocalcin levels did not differ between patients and controls and did not show any significant correlations with BMD, BASDAI, or BASRI in men with AS. Conclusions: Elevated CTX-I reflects disease activity and loss of femoral BMD while elevated CTX-II levels correlate well with radiographic damage of the spine, suggesting the usefulness of these markers for monitoring disease activity, loss of BMD, and radiographic damage in men with AS.

Key Words: Ankylosing spondylitis, bone mineral density, C-terminal telopeptide fragments of type I collagen, C-terminal telopeptide fragments of type II collagen, radiographic damage

INTRODUCTION

Enthesitis and syndesmophytosis are pathological hallmarks of AS. Progressive stiffening of the spine often results from new bone formation induced by chronic inflammation in patients with AS. In an apparent contradiction, vertebral osteoporosis is also commonly seen in cases of AS. Bone loss predominates at the spine and femurs, and vertebral fractures constitute a non-negligible cause of morbidity. However, it is not certain which subsets of patients with AS are susceptible to the progression of new bone formation or osteoporosis, and few laboratory markers have proven to reliably indicate either disease activity or loss of BMD in patients with AS.

Although syndesmophytosis represents increased new bone formation in patients with AS, previous reports show that the majority of patients with advanced AS have decreased BMD. The reason for this discrepancy is not clear, nevertheless, it has been suggested that the bone quality of patients with AS may be influenced by various confounders, such as the degree of inflammation, and that bone growth and bone loss occur in parallel. Besides the coexistence of both new bone formation and bone resorption in patients with AS, the pathology of this disease differs from that of other articular disorders in that it is charac-
terized by a greater tendency for involvement of cartilaginous joints, including intervertebral discs and manubrosternal joints. In this regard, biochemical markers that reflect bone and cartilage turnover may be useful tools in monitoring disease activity, osteoporosis, and radiographic damage in patients with AS as well as in identifying the subset of patients at particular risk for serious morbidities associated with the disease.

Assays for the proteins produced by osteoblasts, such as BALP and osteocalcin, have commonly been used to assess the degree of bone formation. In addition, measurement of CTX-I is one of the most valuable assessments of osteoclastic activity, whereas urinary CTX-II specifically reflect cartilage degradation. Previous studies have shown that the levels of these bone and cartilage turnover markers can be used to monitor changes of BMD and predict the progression of joint damage in several articular diseases. The value of tracking bone formation and resorption markers in patients with AS is well recognized, and several previous studies have established that increased bone degradation markers are associated with increased disease activity and loss of BMD in patients with AS. The association between bone degradation markers and radiographic damage of the spine has not clearly been elucidated, however, the role of cartilage degradation markers has not yet been reported in patients with AS.

To evaluate the potential uses of bone and cartilage turnover markers in understanding disease pathogenesis and in monitoring the morbidities associated with AS, we determined the levels of these markers in patients with AS and investigated their association with disease activity, BMD, and radiographic damage of the spine.

**PATIENTS AND METHODS**

**Study subjects**

This cross-sectional study included 35 men with newly diagnosed AS (mean age, 28.8 - 8.6 years; range, 18 - 37 years) who visited the Division of Rheumatology at Severance Hospital, Yonsei University Medical Center, between January 2003 and January 2004. All patients fulfilled the modified New York criteria for AS, and the mean disease duration from symptom onset to study enrollment was 20.1 - 15.0 months (range, 6.0 - 61.0 months). Patients who had been treated with calcium, vitamin D, bisphosphonate, glucocorticoids, anticonvulsants, or anticoagulants prior to study enrollment, and those with a medical illness or spinal disease other than AS, such as a herniated spinal disc, were excluded. Patients with peripheral arthritis were also excluded because the presence of peripheral arthritis can influence the levels of bone and cartilage turnover markers. Seventy age-matched healthy men (mean age, 29.2 - 8.8 years; range, 19.0 - 37.0 years) were enrolled as control subjects. This study was approved by the ethics committee of our institute, and signed informed consent was obtained from all study participants.

**Clinical assessments**

BMD of men with AS was measured at the posteroanterior lumbar spine (L1-4) and femoral neck using dual energy X-ray absorptiometry (DXA). Results are expressed as BMD in g/cm² and T scores using a Hologic QR4500 densitometer. T score was defined as the standard deviation by which a patient's BMD differed from the mean BMD of normal Korean young controls, provided by the Korean branch of the densitometer's manufacturer. Validated clinical criteria from the AS assessment working group were also measured, including BASDAI for disease activity and BASRI of spine for radiological damage.

**Biochemical assessments**

Biochemical assays were performed on fasting morning blood samples and fasting second morning void urine samples obtained concurrently with assessments of clinical parameters. Serum BALP and osteocalcin levels were determined using enzyme immunoassay (ELISA, Metra Biosystems, Mountain View, CA, USA), according to the manufacturer's protocol. Both intra- and inter-assay coefficients of variation for tests were lower than 7%.
Urinary CTX-I levels were measured by urine CrossLaps enzyme-linked immunosorbent assay (ELISA; Nordic Bioscience Diagnostics, Herlev, Denmark), which uses a polyclonal rabbit antiserum containing an antibody against a sequence in the C-terminal telopeptide α1 chain of human type I collagen. Both intra- and inter-assay coefficients of variation were both than 9%. Urinary CTX-II levels were determined by urine CartiLap ELISA (Nordic Bioscience Diagnostics) based on a monoclonal antibody raised against the EKGPDP sequence of the human C-terminal telopeptide fragment of type II collagen, with intra- and inter-assay coefficients of variation below 6% and 8%, respectively.

ESR was measured by a modified Westergren method (reference range <15 mm/hr in men and <20 mm/hr in women), and CRP level was determined by immunonephelometry (reference range <0.8 mg/dL in all subjects; BN-II nephelometer, Dade-Behring, Marburg, Germany).

**Statistical analysis**

All data are expressed as mean±SD, and data from biochemical assays represent duplicate measurements. Results were analyzed using Mann-Whitney U test, and correlations were evaluated using Pearson’s correlation test. P values less than 0.05 were considered statistically significant.

**RESULTS**

**Comparison between patients and controls**

The demographic, clinical, and laboratory characteristics of patients with AS and of control subjects are summarized in Table 1. Mean age of patients with AS was not different from that of controls. Mean ESR and CRP levels of patients with AS were significantly higher than those of the controls as were urinary CTX-I (p = 0.014) and CTX-II (p < 0.001) levels. The differences between patients with AS and controls for BALP and osteocalcin were not statistically significant.

**Correlations between biochemical and clinical parameters**

Table 2 shows correlations between biochemical and clinical parameters in patients with AS. The age and disease duration were not significantly related to any of the clinical or biochemical parameters, although CRP levels correlated well with BASDAI (r = 0.612, p < 0.001) while ESR did not. Among the clinical parameters, significant inverse correlations were found between BASDAI and femoral neck BMD (r = -0.493, p = 0.003) and between BASDAI and femoral neck T scores (r = -0.568, p < 0.001) in patients with AS.

Serum BALP and osteocalcin levels did not correlate with any of the clinical or laboratory parameters. Urinary CTX-I levels showed significantly inverse correlations with femoral neck BMD (r = -0.414, p = 0.030) and femoral neck T scores (r = -0.399, p = 0.037), but not with spinal BMD or T score. There were significantly positive correlations between urinary CTX-I levels and BASDAI (r = 0.445, p = 0.016) as well as between urinary CTX-I and CRP levels (r = 0.491, p = 0.006). A significantly positive correlation was also found between urinary CTX-II levels and spinal BASRI (r = 0.472, p = 0.010).

**DISCUSSION**

In the present study, an elevated urinary CTX-I level, a marker for bone resorption, was found to reflects increased disease activity and decreased BMD in men with AS. Although this study enrolled young men (mean 28.8 years) so as to exclude confounding factors of osteoporosis, such as age, sex, and menopause, both BMD and T scores measured in men with AS in this study were relatively lower than in normal Korean young men. In addition, a strong correlation was found between disease activity and loss of femoral neck BMD. Previous studies have demonstrated that patients with AS have normal bone formation marker levels and increased bone resorption markers, and that bone resorption markers reflect disease activity and the development of osteoporosis in patients with AS. In agreement with these previous findings, our patients with AS had...
**Table 1. Main Characteristics of Patients with Ankylosing Spondylitis and Controls**

| Characteristics                          | AS patients (n = 35) | Controls (n = 70) | p value |
|------------------------------------------|----------------------|-------------------|---------|
| Age (yrs)                                | 28.8 ± 8.6           | 29.2 ± 8.8        | 0.821   |
| Disease duration (months)                | 20.1 ± 15.0          | -                 | -       |
| DXA findings                             |                      |                   |         |
| Lumbar vertebrae 1-4                     |                      |                   |         |
| BMD (g/cm²)                              | 1.01 ± 0.19          | -                 | -       |
| T score                                  | -0.37 ± 0.60         | -                 | -       |
| Femur neck                               |                      |                   |         |
| BMD (g/cm²)                              | 0.81 ± 0.12          | -                 | -       |
| T score                                  | -1.11 ± 0.54         | -                 | -       |
| BASDAI                                   | 7.0 ± 4.6            | -                 | -       |
| BASRI-spine                              | 3.2 ± 2.1            | -                 | -       |
| Biomarker levels                         |                      |                   |         |
| Serum BALP (IU/L)                        | 19.1 ± 5.3           | 16.0 ± 6.0        | 0.101   |
| Serum osteocalcin (ng/mL)                | 11.7 ± 3.3           | 8.2 ± 3.9         | 0.060   |
| Urine CTX-I (µg/mmol Cr)                 | 279.9 ± 84.4         | 152.5 ± 91.9      | 0.014   |
| Urine CTX-II level (µg/mmol Cr)          | 472.3 ± 159.0        | 259.1 ± 125.4     | 0.001   |
| Acute phase reactants                    |                      |                   |         |
| ESR, mm/hour                             | 37.7 ± 20.1          | 9.7 ± 4.0         | 0.001   |
| CRP, mg/dL                               | 1.1 ± 0.8            | 0.3 ± 0.1         | 0.003   |

DXA, dual energy X-ray absorptiometry; BMD, bone mineral density; BASDAI, Bath ankylosing spondylitis disease activity index; BASRI, Bath AS radiographic index; BALP, bone specific alkaline phosphatase; CTX, C-terminal telopeptide fragments; Cr, creatinine; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

**Table 2. Correlations between Biochemical Parameters and Clinical Parameters in Patients with Ankylosing Spondylitis**

| Biomarker levels                          | ESR | CRP | BASDAI | BASRI-spine | Lumbar BMD | Lumbar T score | Femur neck BMD | Femur neck T score |
|-------------------------------------------|-----|-----|--------|-------------|------------|----------------|-----------------|-------------------|
| Serum BALP (IU/L)                         | 0.141 | 0.127 | 0.190 | 0.211 | -0.266 | -0.227 | -0.012 | -0.088 |
| Serum osteocalcin (ng/mL)                 | 0.189 | 0.211 | 0.005 | -0.196 | -0.037 | -0.102 | -0.270 | -0.244 |
| Urine CTX-I (µg/mmol Cr)                  | 0.253 | 0.491* | 0.445* | 0.186 | -0.300 | -0.274 | -0.414* | -0.399* |
| Urine CTX-II (µg/mmol Cr)                 | 0.109 | 0.099 | 0.271 | 0.472* | 0.008 | 0.115 | 0.197 | 0.317 |

BALP, bone specific alkaline phosphatase; CTX, C-terminal telopeptide fragments; Cr, creatinine; BASDAI, Bath ankylosing spondylitis disease activity index; BASRI, Bath AS radiographic index; BMD, bone mineral density.

Results are shown as the correlation coefficients, calculated using Pearson’s correlation test. *, p value < 0.05 by Pearson’s correlation test.
normal bone formation markers and an increased bone resorption marker, and the increased bone resorption marker showed significantly positive correlation with disease activity and significantly inverse correlation with BMD in men with AS. These data support the theory that patients with AS have unbalanced bone turnover, and that inflammatory activity can alter bone metabolism and lead to osteoporosis.\(^{15-18}\)

In our study, urinary CTX-I levels were significantly correlated only with loss of femoral neck BMD but not with loss of spinal BMD. Previously, Bronson et al. showed that BMD was significantly lower at the femur neck but not the posteroanterior lumbar spine in patients with AS than in control subjects,\(^{22}\) and they suggested that ankylosis of the posterior elements of the spine might contribute to the false elevation of posteroanterior lumbar BMD measured by DXA. Baek et al. also showed that the progression of bone loss may be reflected more reliably at proximal femur sites than at the lumbar spine.\(^{23}\) Thus, the possibility exists that syndesmophytosis, a process of new bone formation, caused an over-estimation of BMD in our study since it was measured at the posteroanterior lumbar spine.

The role of CTX-II measurement has been emphasized in several articular diseases other than AS. Our data demonstrate that urinary CTX-II levels, which specifically indicate degradation of cartilage, are also increased and related to radiographic damage of the spine in patients with AS. Significant associations of urinary CTX-II level with long-term progression of joint destruction in rheumatoid arthritis and with joint damage in severe osteoarthritis have been reported.\(^{9-11}\) However, the role of this cartilage degradation marker has not been determined in patients with AS, and our study is the first to report a significant correlation between increased urinary CTX-II levels and radiographic damage of the spine in patients with AS.

It is interesting to note that only the cartilage degradation marker showed a significant association with the parameter reflecting spinal damage in our patients. Radiographic damage of the spine, as assessed in this study by BASRI-spine, reflects syndesmophytosis,\(^{21}\) and syndesmophytosis represents pathological new bone formation in the spine. But bone formation markers were not found to be associated with BASRI-spine, and their serum levels in patients with AS were not different from those in controls. The significant association between a cartilage degradation marker and radiographic damage of the spine observed in this study suggests a role for cartilage in the pathogenesis of syndesmophytosis in patients with AS.

The pathogenetic mechanisms responsible for the spinal damage and ankylosis observed in patients with AS are unknown. Although enthesitis is a distinctive feature of AS, its relevance to the pathogenesis of synovitis and its significance to the pathogenesis of disease at various other articular and extra-articular sites typically affected by AS, such as the sacroiliac joint, hip joint, and anterior uvea, are questionable. The disparate clinical, pathological, radiological, and immunological data in AS are more consistent with an alternative hypothesis of primary autoimmunity to cartilage and, in particular, to fibrocartilage.\(^7\) A peculiar predilection at fibrocartilaginous sites, including the intervertebral discs, manubrio-sternal joints, and symphysis pubis, is widely appreciated in AS.\(^{24,25}\) Proteoglycans present in cartilage and fibrocartilage have been shown to be involved in the immune response in spondyloarthritides,\(^{26,27}\) and a histopathological study of sacroiliitis showed that a proliferative process of cartilage metaplasia and endochondral ossification, fibrosis, and formation of woven bone led to ankylosis.\(^{28}\) These observations suggest that cartilage, particularly fibrocartilage, may be another target of inflammation in AS and may be involved in syndesmophytosis. In this regard, the significant association between a cartilage degradation marker and spinal damage observed in this study supports the role of cartilage and its degradation in the pathogenesis of AS. Furthermore, our finding suggests that measurement of CTX-II levels can be useful in monitoring spinal damage in patients with AS. Further investigations enrolling a larger number of patients are needed to confirm the relationship found in this study and to gain better understanding of the role of cartilage in the pathogenesis of AS, particularly in the process of syndesmophytosis.

In summary, urinary CTX-I and CTX-II were
elevated in men with AS and correlated well with disease activity, osteoporosis of the femur neck, and radiographic damage of the spine. Our findings suggest that these markers can be used to monitor disease activity, loss of BMD, or radiographic damage of the spine as well as to identify patients with AS who are at particular risk for serious complications and would thus benefit from more aggressive treatment early in the disease.

ACKNOWLEDGEMENTS

The authors wish to thank Sung Min Myoung, PhD, at the Department of Biostatistics, Yonsei University College of Medicine, for his statistical consultation.

REFERENCES

1. Calin A. Osteoporosis and ankylosing spondylitis. Br J Rheumatol 1991;30:318-9.
2. El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999;26:2205-9.
3. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis. J Rheumatol 1999;26:966-70.
4. Geusens P, Hossein D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:335-9.
5. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-8.
6. Capaci K, Hegeguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 2003;44:379-84.
7. Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 2000;27:2295-301.
8. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997;30:573-93.
9. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
10. Christgau S, Garnero P, Fledeulis C, Moniz C, Ensing M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
11. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30.
12. Landewe R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-9.
13. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60:619-26.
14. Lehmman HJ, Mouritzten U, Christgau S, Cloos PA, Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002;61:530-3.
15. Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 2000;5:507-11.
16. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozczuk W, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
17. Toussiot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium crosslinks, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 1999;38:21-7.
18. Marhofer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
20. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
21. Calin A, Mackay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999;26:988-92.
markers of bone metabolism in ankylosing spondylitis. J Rheumatol 1998;25:929-35.
23. Baek HJ, Kang SW, Lee YJ, Shin KC, Lee EB, Yoo CD, et al. Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005;26:30-4
24. Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthritis at entheses and related sites. J Anat 2001;199: 503-26.
25. Buckwalter JA, Hunziker EB. Articular cartilage morphology and biology. In: Archer CW, Caterson B, Benjamin M, Ralphs JR, editors. Biology of the synovial joint. Amsterdam: Harwood Academic Publisher; 1999. p.75-100.
26. Poole AR. The histopathology of ankylosing spondylitis: are there unifying hypotheses? Am J Med Sci 1998;316: 228-33.
27. Kuon W, Kuhne M, Busch DH, Atagunduz P, Seipel M, Wu P, et al. Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthritis. J Immunol 2004;173:4859-66.
28. François RJ, Gardner DL, Degraeve EJ, Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000;43:2011-24.